{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:30:11Z","timestamp":1784716211370,"version":"3.55.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Pregabalin misuse and dependence have become emerging concerns in recent years, particularly in regions where traditional drug-related crimes have been curbed, prompting users to seek alternative substances. Although pregabalin is primarily used for treating conditions such as epilepsy, neuropathic pain, and generalized anxiety disorder, its sedative and euphoric effects make it prone to misuse. This case report presents a 20-year-old male who developed pregabalin dependence after using the drug intermittently at escalating doses over a year. He experienced withdrawal symptoms including palpitations, tremors, irritability, insomnia, and auditory hallucinations upon cessation of the drug, which were alleviated by resuming pregabalin use. Upon admission, he was diagnosed with pregabalin dependence, hyperuricemia, and thyroid nodules. The patient underwent a comprehensive treatment plan involving benzodiazepines, antidepressants, and antipsychotics, leading to substantial improvement in mood, anxiety, psychotic symptoms, and withdrawal symptoms. This case highlights the growing issue of pregabalin misuse, the associated withdrawal symptoms, and the importance of early intervention and systematic treatment strategies. It emphasizes the need for stricter prescription controls, patient education on the risks of misuse, and multidisciplinary approaches to the treatment of pregabalin dependence. Further research is necessary to better understand the mechanisms behind pregabalin misuse and to develop improved prevention and treatment protocols.<\/jats:p>","DOI":"10.3389\/fpsyt.2025.1511168","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T15:57:57Z","timestamp":1742572677000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A case report of pregabalin misuse leading to drug dependence"],"prefix":"10.3389","volume":"16","author":[{"given":"Yaan","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiafeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2014.08.004","article-title":"Prescription drug abuse: from epidemiology to public policy","volume":"48","author":"McHugh","year":"2014","journal-title":"J Subst Abuse Treat"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v68n0320a","article-title":"Gabapentin abuse, and delirium tremens upon gabapentin withdrawal","volume":"68","author":"Pittenger","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and misuse of pregabalin and gabapentin: A systematic review update","volume":"81","author":"Evoy","year":"2020","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00985-6","article-title":"Current evidence on abuse and misuse of gabapentinoids","volume":"43","author":"H\u00e4gg","year":"2020","journal-title":"Drug Saf"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060371","article-title":"Pregabalin: An antiepileptic agent useful for neuropathic pain","volume":"64","author":"Blommel","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13115","article-title":"Pregabalin: A range of misuse-related unanswered questions","volume":"25","author":"Schifano","year":"2019","journal-title":"CNS Neurosci Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10100736","article-title":"What about \"Pharming\"? Issues regarding the misuse of prescription and over-the-counter drugs","volume":"10","author":"Chiappini","year":"2020","journal-title":"Brain Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0359-y","article-title":"A decade of gabapentinoid misuse: An analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' database","volume":"30","author":"Chiappini","year":"2016","journal-title":"CNS Drugs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/rmhp.s168504","article-title":"Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance","volume":"11","author":"Peckham","year":"2018","journal-title":"RMHP Volume"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0853-y","article-title":"A signal for an abuse liability for pregabalin\u2014results from the Swedish spontaneous adverse drug reaction reporting system","volume":"66","author":"Schwan","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6747","article-title":"Bad medicine: gabapentin and pregabalin","volume":"347","author":"Spence","year":"2013","journal-title":"BMJ"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4997\/jrcpe.2017.402","article-title":"Gabapentin and pregabalin: do the benefits outweigh the harms","volume":"47","author":"Morrison","year":"2017","journal-title":"J R Coll Physicians Edinb"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13892","article-title":"Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France","volume":"85","author":"Driot","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"B14","article-title":"Pregabalin can cause addiction and withdrawal symptoms","volume":"177","author":"Nordgaard","year":"2015","journal-title":"Ugeskrift l\u00e6ger"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4103\/0972-6748.328855","article-title":"A case of pregabalin addiction","volume":"30","author":"Chaudhury","year":"2021","journal-title":"Ind Psychiatry J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18116000","article-title":"Representations of psychoactive drugs' use in mass culture and their impact on audiences","volume":"18","author":"Motyka","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ph3072333","article-title":"The health effect of psychostimulants: A literature review","volume":"3","author":"Favrod-Coune","year":"2010","journal-title":"Pharmaceutics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.lssr.2022.02.001","article-title":"Medial prefrontal cortex and hippocampus in mice differently affected by simulated microgravity and social isolation associated with the alternation of emotional and cognitive functions","volume":"33","author":"Liang","year":"2022","journal-title":"Life Sci Space Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav3928","article-title":"Relating addiction and psychiatric disorders","volume":"361","author":"Vink","year":"2018","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000247","article-title":"What we know about massively multiplayer online role-playing games","volume":"28","author":"Chen","year":"2020","journal-title":"Harv. Rev Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.00083","article-title":"Pregabalin as a pain therapeutic: beyond calcium channels","volume":"14","author":"Alles","year":"2020","journal-title":"Front Cell Neurosci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci8040073","article-title":"Abuse of prescription drugs in the context of novel psychoactive substances (NPS): A systematic review","volume":"8","author":"Schifano","year":"2018","journal-title":"Brain Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02966.x","article-title":"The adverse event profile of pregabalin: A systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Zaccara","year":"2011","journal-title":"Epilepsia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/24750573.2018.1452523","article-title":"First-episode psychosis induced by pregabalin withdrawal: a case report","volume":"28","author":"Gundogmus","year":"2018","journal-title":"Psychiatry Clin Psychopharmacol - PCP"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-023-04696-x","article-title":"The effect of gabapentin and pregabalin administration on memory in clinical and preclinical studies: a meta-analysis and systematic review","volume":"23","author":"Behroozi","year":"2023","journal-title":"BMC Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-016-1230-x","article-title":"Effect of pregabalin on contextual memory deficits and inflammatory state-related protein expression in streptozotocin-induced diabetic mice","volume":"389","author":"Sa\u0142at","year":"2016","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-024-00595-5","article-title":"Impaired synaptic plasticity and decreased glutamatergic neuron excitability induced by SIRT1\/BDNF downregulation in the hippocampal CA1 region are involved in postoperative cognitive dysfunction","volume":"29","author":"Wu","year":"2024","journal-title":"Cell Mol Biol Lett"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.548505","article-title":"Glutamate systems in DSM-5 anxiety disorders: their role and a review of glutamate and GABA psychopharmacology","volume":"11","author":"Nasir","year":"2020","journal-title":"Front Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2006.10.008","article-title":"Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)","volume":"73","author":"Bialer","year":"2006","journal-title":"Epilepsy Res"},{"key":"B30","first-page":"4","article-title":"Glutamatergic theories of schizophrenia","author":"Javitt","year":"2010","journal-title":"Israel J Psychiatry related Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcz025","article-title":"Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development","volume":"1","author":"Lerner","year":"2019","journal-title":"Brain. Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2012.10.3.136","article-title":"Transcriptional mechanisms of drug addiction","volume":"10","author":"Nestler","year":"2012","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.13175\/swjpcc059-15","article-title":"Acute pregabalin withdrawal: a case report and review of the literature","volume":"10","author":"Barrett","year":"2015","journal-title":"Southwest J Pulmonary Crit Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-020-01875-5","article-title":"The neurotoxic effect of long-term use of high-dose Pregabalin and the role of alpha tocopherol in amelioration: implication of MAPK signaling with oxidative stress and apoptosis","volume":"393","author":"Taha","year":"2020","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0164-4","article-title":"Misuse and abuse of pregabalin and gabapentin: cause for concern","volume":"28","author":"Schifano","year":"2014","journal-title":"CNS Drugs"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.569912","article-title":"Antipsychotic withdrawal symptoms: A systematic review and meta-analysis","volume":"11","author":"Brandt","year":"2020","journal-title":"Front Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","first-page":"CD013495","DOI":"10.1002\/14651858.cd013495.pub2","article-title":"Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults","volume":"2021","author":"Van Leeuwen","year":"2021","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1511168\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T15:58:05Z","timestamp":1742572685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1511168\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":38,"alternative-id":["10.3389\/fpsyt.2025.1511168"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1511168","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"article-number":"1511168"}}